Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets, and forecast a similar performance for the year ahead as it implements a new strategy.
Full-year reported revenue grew 3% to 27.87 billion Danish kroner, while the operating profit margin before special items was 28%, the company said.
Growth was led by its Continence Care and Voice & Respiratory Care divisions, though the company noted that sales in China declined and its Interventional Urology business was impacted by a product recall.
The results come during what the company described as a transitional period, following the launch of its new five-year "Impact4" strategy in September.
"2024/25 has been a transitional year for Coloplast, and I now look forward to 2025/26 and the execution of our new 2030 strategy, Impact4,” said interim CEO Lars Rasmussen.
For the 2025/26 fiscal year, Coloplast guided for organic revenue growth of around 7%, which it expects to translate to reported growth of 4-5% after negative currency effects.
The company's board recommended a total dividend of 23.00 Danish kroner per share, an increase from 22.00 kroner in the prior year.
More from this issuer
Related coverage
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets as it navigates a period of strategic and leadership transition.
Coloplast interim Chief Executive Lars Rasmussen will step down from the company's board of directors, the latest leadership change at the Danish medical device maker as it implements a new strategy.
Danish medical device maker Coloplast on Tuesday unveiled a new five-year strategy that tempers its long-term growth forecast.
Danish medical device maker Coloplast on Tuesday tempered its long-term growth forecast as it unveiled a new five-year strategy, dubbed "Impact4."